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difference being that the primary site of oligometastases was 
uncontrolled (sync-oligometastases) or controlled (oligo-
recurrence). The goal of this multicenter study was to 
evaluate treatment outcomes and to evaluate factors 
affecting relapse-free survival (RFS) after stereotactic body 
radiotherapy (SBRT) for pulmonary oligometastases. 
Materials and Methods: A total of 96 patients (65 males and 
31 females) who received SBRT for oligometastatic lung 
tumors between January 2004 and April 2014 at 4 high-
volume institutions in Japan were enrolled in this 
retrospective study. The primary sites were the colorectum 
(n=25), lung (n=24), head and neck (n=8), uterus (n=8) and 
others (n=31), and the pathologies of primary cancers were 
adenocarcinoma (n=49), squamous cell caricinoma (n=19), 
others (n=12) and pathologically unproven (n=16). The 
median tumor diameter was 19 mm (range, 6-42 mm). Ten 
cases were sync-oligometastases and 79 cases were oligo-
recurrences. The median disease-free interval (DFI) between 
initial therapy and SBRT was 24 months (range, 0-246 
months). The median calculated biological effective dose was 
105.6 Gy (range, 75-134.4 Gy) using the LQ model with 
alpha/beta = 10 Gy. The prescribed dose was delivered to the 
isocenter (n=56) or covering 95% of the PTV (D95, n=40). 
Cumulative overall survival (OS), local control rate (LCR) and 
RFS rate were calculated using Kaplan-Meier curves, and the 
log-rank test was used to compare the curves. Multivariate 
analysis for RFS was performed using a Cox proportional 
hazards model. Statistical significance was defined as a value 
of p < 0.05 in this study. 
Results: The median follow-up periods were 21 months 
(range, 1-119 months) for all patients and 32 months (range, 
1-119 months) for survivors. The 3-year OS, LCR and RFS rates 
were 52%, 75% and 25%, respectively. Radiation pneumonitis 
of grade 3 was found in 2 patients and gastrointestinal 
toxicity of grade 4 was found in 1 patient. No grade 5 toxicity 
occurred. The 3-year RFS for sync-oligometastases was 0% 
and that for oligo-recurrence was 28% (Figure, p < 0.01). The 
3-year RFS for the subgroup of DFI < or = 24 months and that 
for the subgroup of DFI > 24 months were 17% and 34%, 
respctively (p = 0.01). In multivariate analysis, sync-
oligometastases (p = 0.01), multiple oligometastatic tumors 
(p = 0.01) and D95 (p = 0.02) were significantly unfavorable 
factors for RFS. 
 
 
 
Conclusions: In SBRT for oligometastatic lung tumors, control 
of the primary site is a significant prognostic factor for RFS. 
Single oligo-recurrence tumor in the lung could be a good 
candidate for SBRT.  
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Purpose/Objective: In the multicenter PET-Plan study, which 
is comparing FDG–PET based treatment planning for 
chemoradiotherapy of NSCLC with conventional target 
volumes in terms of loco-regional progression the cardiac 
dose is an important planning criterion. The presented study 
examines the extent of deviation of delineated heart 
contours from two study centers compared to the per- 
rotocol delineation and its effect on the heart dose with 
particular consideration of the dose distribution. 
Materials and Methods: Heart contours from 59 patients of 
two study centers were re-delineated in strict adherence to 
the study protocol (starting just below the level in which the 
pulmonary trunk branches into the left and right PA, ending 
where the heart blends with the diaphragm). The volumes 
and dose values of the original contours of both centers were 
compared with the values resulting from the protocol-
compliant delineation with Student's t - test. 
Results: The original heart contours of the centers were too 
small in every case compared to the respected protocol 
specification [684,10 ± 302,37 cm3 versus 868,18 ± 219,97 
cm3]. The difference was highly significant with 
p=1.267*10-14. The heart dose-volume parameters of the 
original study center contours were compared with the 
results from the protocol-oriented delineation values, 
significantly smaller (Dmax: p=0,00068; V5:  p=0,00013; 
V40: p=3,4*10-9). In three cases, the study protocol’s 
restriction (V40 ≤ 50 %) was exceeded after correct 
delineation of the heart with a percentage of 54,55%, 60,12% 
respectively 58,04%. 
Conclusions: Incorrect delineation of the heart can lead to a 
misinterpretation of the actual organ dose. In individual 
cases this can be associated with the presumption that 
specific dose restrictions are met, even though dose limits 
are already exceeded. 
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Purpose/Objective: To evaluate the feasibility and efficacy 
of simultaneous integrated boost intensity-modulated 
radiation therapy (SIB-IMRT) in patients with limited-disease 
small cell lung cancer (LD-SCLC). 
Materials and Methods: Patients with LD-SCLC were treated 
with SIB-IMRT within 1 week after completion of 2 cycles of 
induction chemotherapy. Then 2-4 cycles of adjuvant 
chemotherapy were administered within 1 week after SIB-
IMRT. Irradiation was given accelerated hyper-fractionated 
with the prescribed dose 57 Gy at 1.9 Gy twice daily to the 
